Biotech

All Articles

AstraZeneca pays for CSPC $100M for preclinical heart disease medication

.AstraZeneca has settled CSPC Drug Group $one hundred million for a preclinical heart attack medicin...

Zephyrm seeks Hong Kong IPO to fund phase 3 cell treatment trials

.Zephyrm Bioscience is gusting towards the Hong Kong stock market, submission (PDF) for an IPO to ba...

Frazier Lifestyle Sciences collects $630M for small, mid-cap biotechs

.Frazier Everyday life Sciences has sourced a further $630 million for its own fund concentrated on ...

GigaGen amasses as much as $135M BARDA bucks to beat botulism

.Antitoxin aficionado GigaGen, a subsidiary of Spanish biopharma Grifols, is increase its own tech t...

GPCR organization Septerna files for IPO on toughness of preclinical information

.Septerna will determine exactly how a biotech without "any relevant clinical data" fares in the ove...

Kurma closes first $154M payload for biggest biotech fund yet

.European VC organization Kurma Partners has unveiled its newest biotech fund, with 140 million euro...

Prothena markets one exec while one more leaves behind-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of notable leadership hirings, shootings and al...

Editas cashes in on Tip Cas9 licensing civil rights for $57M

.Against the scenery of a Cas9 license fight that refuses to die, Editas Medication is actually mone...

Ultragenyx modifies gene treatment application to dial up efficacy

.A minority of clients taking Ultragenyx Pharmaceutical's Wilson disease genetics therapy UX701 have...

Biopharma discharge cost supports in Q3: Tough Biotech evaluation

.As summer season warm turns to cool winds, wishes that this year will deliver common field comfort ...